About BridgeLine Translational Partners™
BridgeLine Translational Partners™ is a boutique biotech consulting group, R&D and venture partner.
We help early-stage biotechs, translational teams, and investors turn early findings into:
Decision-grade development strategies—from target identification and indication selection to nonclinical plans aligned with clinical use and patient value
Investor- and partner-ready materials that withstand scrutiny and enable confident decisions
Lean, expert execution support that keeps progress focused and capital-efficient
Scientific diligence support that de-risks investments and validates translational feasibility
Where We’re Most Effective
Therapeutic Areas & Modalities: Indication- and modality-agnostic. Every engagement starts with the Target Product Profile (TPP) and maps back to patient impact.
Situations We Support:
Translating early data into a credible, fundable development plan
Evaluating early-stage assets for investment, licensing, or platform expansion
Preparing materials and positioning for fundraising or BD discussions
Aligning preclinical work with clinical goals while managing budget and risk
Example Outcomes
Emerging Biotech Program – Consolidated early findings into a TPP-anchored plan; developed a focused nonclinical roadmap; delivered investor materials that helped biotech reach funding goals.
Academic Spinout – Translated grant-stage science into a development-quality package; supported pitch materials and early partner outreach
Venture Diligence – Conducted independent evaluation of translational rationale, risk, and feasibility; helped guide go/no-go decision
Platform Company – Prioritized pipeline assets using indication fit and data maturity; produced partner-facing materials and risk registers for BD
Clinical-Stage Company – Pressure-tested scientific claims; streamlined nonclinical plans to conserve capital while maintaining decision power
Interested in exploring a fit? Schedule a 30‑minute initial consultation, or reach us at info@bridgelinetranslational.com.
Leadership
Timothy S. Luongo, PhD, MSTR — Founder & Principal
Timothy has held roles across discovery, nonclinical strategy, and external innovation at companies including Sarepta Therapeutics, Spark Therapeutics (Roche), and StrideBio. At Sarepta, he supported scientific diligence, alliance management, and program onboarding as part of the external innovation team. At Spark, he led cross-functional efforts spanning discovery through IND/CTA strategy. At StrideBio, he directed early-stage programs, shaped target selection, and designed preclinical models in close coordination with regulatory and clinical teams.
Earlier in his career, he worked in organic process chemistry at Cephalon (now Teva) and conducted immunology research at the NIH Vaccine Research Center. He completed postdoctoral research at the University of Pennsylvania’s Institute for Diabetes, Obesity, and Metabolism and served on Penn’s Institutional Review Board, reviewing clinical protocols and informed consent documents.
He has a strong academic foundation, having worked on complex mechanistic research questions and advanced them toward translational application. He earned his PhD in Biomedical Sciences from Temple University, conducting his graduate research at the Temple Center for Translational Medicine, and a Master of Science in Translational Research from the University of Pennsylvania with a focus on regulatory affairs and drug development. He also holds a Bachelor of Science in Biochemistry.
Timothy has an extensive publication record in high-impact journals including Nature, Cell, Immunity, Circulation, Cell Reports, and Nature Cardiovascular Research, and has been awarded prestigious grants and honors for his work.